Mobile

A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Primary Hypercholesterolemia and High Cardiovascular Risk and not Adequately Controlled with Atorvastatin 20 mg: A Com...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-005002-40

A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Primary Hypercholesterolemia and High Cardiovascular Risk and not Adequately Controlled with Atorvastatin 20 mg: A Comparison of Switching to a Combination Tablet Ezetimibe/Simvastatin (10mg/40mg) versus Doubling the Baseline Dose to Atorvastatin 40 mg

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

In patients with primary hypercholesterolemia and high cardiovascular risk treated with atorvastatin 20 mg and with LDL-Cholesterol blood level (LDL-C) ≥ 100 mg/dl (2.59 mmol/L) and ≤ 160 mg/dl (4.14 mmol/L) at baseline: 1. to assess the incremental LDL-C percentage reduction by switching to ezetimibe/simvastatin (10mg/40mg) compared to atorvastatin 40mg. 2. to evaluate the safety of ezetimibe/simvastatin (10mg/40mg) versus atorvastatin 40 mg.

Critère d'inclusion

  • Primary Hypercholesterolemia

Liens